Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine CR in Alzheimer's Disease
NCT00253214Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2001
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, double-blind trial of galantamine in Alzheimer's disease (AD) (3 arms), sponsored by Johnson & Johnson. Primary endpoints: Alzheimer's Disease Assessment Scale - Cognitive Subscale (11 items) at 24 weeks and Clinician's Interview Based Impression of Change - Plus Caregiver Input at 24 weeks. Started Mar 2001; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00253214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253214.